AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31440799 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA radioligand therapy (PSMA-RLT)
Number of subjects: 0
Study 28892656 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment group
Number of subjects: 40
Study 28892656 — intervention group
Group type: COMPARATOR
Intervention: non-rt-PA treatment group
Number of subjects: 40
Study 25789421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) at 12 mmHg pneumoperitoneum
Number of subjects: 14
Study 25789421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) at 8 mmHg pneumoperitoneum
Number of subjects: 14
Study 25789421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) during suturing
Number of subjects: 14
Study 23666681 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided therapy
Number of subjects: 495
Study 23666681 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 495
Study 21729014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bringing Baby Home psycho‐educational intervention
Number of subjects: 181
Study 21729014 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop prebirth
Number of subjects: 181
Study 21729014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study 21729014 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 181
Study 21729014 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop plus support group
Number of subjects: 181
Study 18504059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Collaborative Chronic Care Model (B-CCM)
Number of subjects: 290
Study 18504059 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290
Study 16472720 — intervention group
Group type: EXPERIMENTAL
Intervention: Misleading cue indicating the taste would be mildly aversive
Number of subjects: 0
Study 16472720 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity among the OFC, rACC, and insula
Number of subjects: 0
Study 15014005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (10 ml of a 0.1% ketorolac rinse solution; n = 38)
Number of subjects: 57
Study 15014005 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml of rinse solution; n = 19)
Number of subjects: 57
Study 15014005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 57
Study 15014005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 11053335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index (HGI) meal
Number of subjects: 8
Study 11053335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) meal
Number of subjects: 8
Study 11053335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Con) meal
Number of subjects: 8
Study 9326833 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate plus lithium
Number of subjects: 24
Study 9326833 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (lithium, carbamazepine, and valproate)
Number of subjects: 24
Study 8463765 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (one cigarette per hour for 6 h)
Number of subjects: 7
Study 8463765 — intervention group
Group type: EXPERIMENTAL
Intervention: Snuffing (one bag‐packed snuff per hour for 6 h)
Number of subjects: 7
Study 8463765 — intervention group
Group type: COMPARATOR
Intervention: Control (refrained from nicotine for 48 h)
Number of subjects: 7
Study 3979291 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin administration (0.25 g/kg body weight)
Number of subjects: 180
Study 3979291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunoglobulin)
Number of subjects: 180
Study 31390883 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Number of subjects: 0
Study 31390883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29725828 — intervention group
Group type: EXPERIMENTAL
Intervention: iv dexmedetomidine 0.5 mcg/kg
Number of subjects: 60
Study 29725828 — intervention group
Group type: COMPARATOR
Intervention: iv lidocaine 2 mg/kg
Number of subjects: 60
Study 26228699 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion barrier applied
Number of subjects: 42
Study 26228699 — intervention group
Group type: COMPARATOR
Intervention: No adhesion barrier applied
Number of subjects: 42
Study 24647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary phylloquinone intake
Number of subjects: 7216
Study 24647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary menaquinone intake
Number of subjects: 7216
Study 24647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in menaquinone intake
Number of subjects: 7216
Study 23167296 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 3‐day bowel preparation
Number of subjects: 40
Study 23167296 — intervention group
Group type: COMPARATOR
Intervention: Only over‐night fasting before surgery
Number of subjects: 40
Study 20103303 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative thoracic epidural analgesia (TEA)
Number of subjects: 40
Study 20103303 — intervention group
Group type: COMPARATOR
Intervention: Postoperative thoracic epidural analgesia (TEA)
Number of subjects: 40
Study 18594088 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen meniscus implant
Number of subjects: 311
Study 18594088 — intervention group
Group type: COMPARATOR
Intervention: Partial meniscectomy
Number of subjects: 311
Study 15964200 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of a commercial red beet juice (RBJ) containing 362.7 mg of betalains
Number of subjects: 6
Study 15964200 — intervention group
Group type: COMPARATOR
Intervention: 500 mL of tap water
Number of subjects: 6
Study 11814217 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolog condition
Number of subjects: 163
Study 11814217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialog condition
Number of subjects: 163
Study 11814217 — intervention group
Group type: COMPARATOR
Intervention: Communicative context
Number of subjects: 163
Study 11814217 — intervention group
Group type: COMPARATOR
Intervention: Individual characteristics of the speaker
Number of subjects: 163
Study 9712921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 5 mg (loading dose 3.75 mg over 1 h)
Number of subjects: 46
Study 9712921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 10 mg (loading dose 7.5 mg over 1 h)
Number of subjects: 46
Study 9712921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7978399 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-based general anesthetic technique
Number of subjects: 50
Study 7978399 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based general anesthetic technique
Number of subjects: 50
Study 7978399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Desflurane and Propofol)
Number of subjects: 50
Study 2500688 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg disodium cromoglycate (DSCG) four times daily
Number of subjects: 24
Study 2500688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 5015036 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐alpha‐methyldopahydrazine
Number of subjects: 20
Study 5015036 — intervention group
Group type: COMPARATOR
Intervention: Levodopa without L‐alpha‐methyldopahydrazine
Number of subjects: 20
Study 30982849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid
Number of subjects: 635
Study 30982849 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR-adjusted)
Number of subjects: 635
Study 30982849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 635
Study 30982849 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 635
Study 29145468 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (scaling and root planing plus oral hygiene instructions, and supportive therapy at 3 and 6 months)
Number of subjects: 40
Study 29145468 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 40
Study 29145468 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions only)
Number of subjects: 40
Study 25100386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 485
Study 25100386 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) therapy
Number of subjects: 485
Study 24050864 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 40
Study 24050864 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 40
Study 24050864 — intervention group
Group type: COMPARATOR
Intervention: TTE
Number of subjects: 40
Study 21478329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding scale regular insulin
Number of subjects: 3000
Study 21478329 — intervention group
Group type: COMPARATOR
Intervention: Weight-based regimen
Number of subjects: 3000
Study 17544528 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 6922
Study 17156181 — intervention group
Group type: COMPARATOR
Intervention: BDI ≥ 10
Number of subjects: 600
Study 17156181 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI < 10
Number of subjects: 600
Study 17156181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of problem focusing and social support seeking
Number of subjects: 600
Study 12755932 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent-coated spacers (CG)
Number of subjects: 50
Study 12755932 — intervention group
Group type: COMPARATOR
Intervention: Non-coated spacers (NCG)
Number of subjects: 50
Study 10629456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation and high-efficiency vacuum cleaner (HEVC)
Number of subjects: 40
Study 10629456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation alone
Number of subjects: 40
Study 10629456 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency vacuum cleaner (HEVC) alone
Number of subjects: 40
Study 10629456 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40
Study 10629456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation and HEVC
Number of subjects: 40
Study 8803526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprafenone administered with food (100 mg)
Number of subjects: 15
Study 8803526 — intervention group
Group type: COMPARATOR
Intervention: Diprafenone administered in fasting state (100 mg)
Number of subjects: 15
Study 8803526 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow hydroxylator of debrisoquine (100 mg with food)
Number of subjects: 15
Study 1323615 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) at doses of 0.67, 1.33, 2.67, or 4 mg/kg
Number of subjects: 22
Study 1323615 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) after chronic dosing
Number of subjects: 22
Study 6387568 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical .03% sodium flurbiprofen
Number of subjects: 70
Study 6387568 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% indomethacin
Number of subjects: 70
Study 6387568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6387568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for indomethacin protocol)
Number of subjects: 70
Study 29247042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 87
Study 29247042 — intervention group
Group type: COMPARATOR
Intervention: Oral paracetamol
Number of subjects: 87
Study 26779816 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTIV (45 min adaptation of motivational interviewing)
Number of subjects: 351
Study 26779816 — intervention group
Group type: COMPARATOR
Intervention: BNI (15 min Brief Negotiated Interview)
Number of subjects: 351
Study 24424781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 53
Study 24424781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 23340006 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption (1859 kJ) followed by rest (BR)
Number of subjects: 12
Study 23340006 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption followed by exercise (BE)
Number of subjects: 12
Study 23340006 — intervention group
Group type: COMPARATOR
Intervention: Exercise without breakfast (FE)
Number of subjects: 12
Study 23340006 — intervention group
Group type: COMPARATOR
Intervention: Rest without breakfast (FR)
Number of subjects: 12
Study 20532194 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health workers (PHW) intervention
Number of subjects: 1336
Study 20532194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1336
Study 18405148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion
Number of subjects: 56
Study 18405148 — intervention group
Group type: COMPARATOR
Intervention: Sodium Diclofenate Slow‐released Tablet
Number of subjects: 56
Study 17087785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 15
Study 17087785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17087785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Number of subjects: 15
Study 12800105 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional oil (FctO) composed of medium chain triacylglycerols (50% of fat), phytosterols (22 mg/kg body weight), and n-3 fatty acids (5% of fat)
Number of subjects: 17
Study 12800105 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional oil (FctO)
Number of subjects: 17
Study 12800105 — intervention group
Group type: COMPARATOR
Intervention: Beef tallow (BT)
Number of subjects: 17
Study 10536550 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg
Number of subjects: 20
Study 10536550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8906050 — intervention group
Group type: EXPERIMENTAL
Intervention: Superpulsed CO2 laser
Number of subjects: 20
Study 8906050 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy and superpulsed CO2 laser
Number of subjects: 20
Study 1809619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase 250,000 IU followed by intravenous heparin along with conventional treatment
Number of subjects: 67
Study 1809619 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 67
Study 6406037 — intervention group
Group type: COMPARATOR
Intervention: RT (extended field radiotherapy)
Number of subjects: 73
Study 6406037 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT (radiotherapy plus adjuvant chemotherapy with vincristine, streptonigrin, cyclophosphamide and prednisone)
Number of subjects: 73
Study 6406037 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 73
Study 6406037 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 73
Study 6406037 — intervention group
Group type: COMPARATOR
Intervention: RT (among patients with unfavorable histology)
Number of subjects: 73
Study 6406037 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT (among patients with unfavorable histology)
Number of subjects: 73
Study 3901875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pirbuterol + theophylline + hydroxyzine
Number of subjects: 0
Study 3901875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pirbuterol + theophylline
Number of subjects: 0
Study 3901875 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 0
Study 3901875 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine + theophylline + hydroxyzine
Number of subjects: 0
Study 3901875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29458404 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel integrated care concept (NICC)
Number of subjects: 2930
Study 29458404 — intervention group
Group type: COMPARATOR
Intervention: Standard care (guideline therapy)
Number of subjects: 2930
Study 27887662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube lubricated with water (n=150)
Number of subjects: 300
Study 27887662 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment of tracheal tubes (n=150)
Number of subjects: 300
Study 24561972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention program
Number of subjects: 1182
Study 24561972 — intervention group
Group type: COMPARATOR
Intervention: Usual health education curriculum
Number of subjects: 1182
Study 21831167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 30
Study 21831167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam co-administered with oral glucose
Number of subjects: 30
Study 21831167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 30
Study 21831167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20689585 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine/sulfadoxine‐pyrimethamine (AQ/SP)
Number of subjects: 690
Study 20689585 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate/amodiaquine (AS/AQ)
Number of subjects: 690
Study 20689585 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine (AL)
Number of subjects: 690
Study 20689585 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide‐treated bednets (ITNs)
Number of subjects: 690
Study 18514551 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 30 mg
Number of subjects: 1207
Study 18514551 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 200 mg
Number of subjects: 1207
Study 18514551 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1207
Study 15347630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon elongation (TE)
Number of subjects: 18
Study 15347630 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcontraction doublet (PCD) torque
Number of subjects: 18
Study 15347630 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical delay
Number of subjects: 18
Study 12853536 — intervention group
Group type: EXPERIMENTAL
Intervention: Active limb mobilization plus electrical stimulation (ALM/ES)
Number of subjects: 24
Study 12853536 — intervention group
Group type: COMPARATOR
Intervention: Active limb mobilization (ALM)
Number of subjects: 24
Study 10385269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporine A
Number of subjects: 0
Study 10385269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 10385269 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 0
Study 8876072 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mizolastine
Number of subjects: 68
Study 8876072 — intervention group
Group type: COMPARATOR
Intervention: 10 mg loratadine
Number of subjects: 68
Study 2065693 — intervention group
Group type: EXPERIMENTAL
Intervention: rolipram
Number of subjects: 50
Study 2065693 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 50
Study 6870319 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied tetracycline hydrochloride-containing fluorescent ointments, creams, lotions, and tinctures
Number of subjects: 50
Study 6870319 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied medications
Number of subjects: 50
Study 6870319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle of the topical preparation
Number of subjects: 50
Study 31785836 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair
Number of subjects: 30
Study 31785836 — intervention group
Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 30
Study 31267983 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic IIEF-5
Number of subjects: 179
Study 31267983 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic IIEF-15
Number of subjects: 179
Study 31267983 — intervention group
Group type: COMPARATOR
Intervention: Paper IIEF-5
Number of subjects: 179
Study 31267983 — intervention group
Group type: COMPARATOR
Intervention: Paper IIEF-15
Number of subjects: 179
Study 27342222 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 68
Study 27342222 — intervention group
Group type: COMPARATOR
Intervention: No salpingectomy
Number of subjects: 68
Study 26019232 — intervention group
Group type: EXPERIMENTAL
Intervention: APTHotline (telephone assessment of partner(s) plus standard PN)
Number of subjects: 199
Study 26019232 — intervention group
Group type: EXPERIMENTAL
Intervention: APTPharmacy (community pharmacist assessment of partner(s) plus routine PN)
Number of subjects: 199
Study 26019232 — intervention group
Group type: COMPARATOR
Intervention: Standard PN alone (patient referral)
Number of subjects: 199
Study 26019232 — intervention group
Group type: EXPERIMENTAL
Intervention: APTHotline
Number of subjects: 199
Study 26019232 — intervention group
Group type: EXPERIMENTAL
Intervention: APTPharmacy
Number of subjects: 199
Study 22820735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention with instructions to log use daily for 6 months
Number of subjects: 43
Study 22820735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention (high adherence group)
Number of subjects: 43
Study 21669577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted propofol (5 mg/mL)
Number of subjects: 86
Study 21669577 — intervention group
Group type: COMPARATOR
Intervention: Undiluted propofol (10 mg/mL)
Number of subjects: 86
Study 19641843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise
Number of subjects: 74
Study 19641843 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 74
Study 19641843 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hospital-based vs home-based exercise
Number of subjects: 74
Study 16781073 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg, 1800 mg, 2600 mg (titrated over 4 doses)
Number of subjects: 16
Study 16781073 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (various doses)
Number of subjects: 16